The Effect of PPI Use on Human Gut Microbiota and Weight Loss in Patients Undergoing Laparoscopic Roux-en-Y Gastric Bypass

Ward, Emily K.; Schuster, Dara; Stowers, Katie; Royse, Amanda K.; Ir, Diana; Robertson, Charles E.; Frank, Daniel N.; Austin, Gregory L.

doi:10.1007/s11695-014-1275-1

Cited by 44 publications

(35 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The role of PPIs in weight gain has been evaluated previously in the context of outcomes of postgastric bypass patients. A study of adult patients that underwent laparoscopic Roux-en-Y gastric bypass found that PPI users 6 months postgastric bypass trended towards less weight loss 44. This finding was postulated to be associated with PPI-induced changes in the gut microbiota.…”

Section: Discussionmentioning

confidence: 99%

Antibiotic and acid-suppression medications during early childhood are associated with obesity

Stark

Susi

Emerick

et al. 2018

Gut

View full text Add to dashboard Cite

ObjectiveGut microbiota alterations are associated with obesity. Early exposure to medications, including acid suppressants and antibiotics, can alter gut biota and may increase the likelihood of developing obesity. We investigated the association of antibiotic, histamine-2 receptor antagonist (H2RA) and proton pump inhibitor (PPI) prescriptions during early childhood with a diagnosis of obesity.DesignWe performed a cohort study of US Department of Defense TRICARE beneficiaries born from October 2006 to September 2013. Exposures were defined as having any dispensed prescription for antibiotic, H2RA or PPI medications in the first 2 years of life. A single event analysis of obesity was performed using Cox proportional hazards regression.Results333 353 children met inclusion criteria, with 241 502 (72.4%) children prescribed an antibiotic, 39 488 (11.8%) an H2RA and 11 089 (3.3%) a PPI. Antibiotic prescriptions were associated with obesity (HR 1.26; 95% CI 1.23 to 1.28). This association persisted regardless of antibiotic class and strengthened with each additional class of antibiotic prescribed. H2RA and PPI prescriptions were also associated with obesity, with a stronger association for each 30-day supply prescribed. The HR increased commensurately with exposure to each additional medication group prescribed.ConclusionsAntibiotics, acid suppressants and the combination of multiple medications in the first 2 years of life are associated with a diagnosis of childhood obesity. Microbiota-altering medications administered in early childhood may influence weight gain.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibiotic and acid-suppression medications during early childhood are associated with obesity

Stark

Susi

Emerick

et al. 2018

Gut

View full text Add to dashboard Cite

show abstract

“…In addition, weight loss is significantly associated with a decrease in the F/B ratio after Roux-en-Y gastric bypass surgery 25. Recently, one study have shown that perioperative PPI use was associated with an increase in Firmicutes and a decrease in Bacteroidetes in severely obese patients before and after laparoscopic Roux-en-Y gastric bypass surgery 26. The changes in bacterial composition in this study were similar to our results, with an increase of Firmicutes evident in the PPI-treated group.…”

Section: Discussionmentioning

confidence: 99%

Impact of Long-Term Proton Pump Inhibitor Therapy on Gut Microbiota in F344 Rats: Pilot Study

Shin

Kim

et al. 2016

Gut and Liver

View full text Add to dashboard Cite

Background/AimsTo evaluate changes in gut microbiota composition following long-term proton pump inhibitor (PPI) treatment.MethodsTwenty-four-week-old F344 rats were fed diets with (n=6) or without (n=5) lansoprazole for 50 weeks. Profiles of luminal microbiota in the terminal ileum were then analyzed. Pyrosequencing of the 16S rRNA gene was performed using an FLX genome sequencer (454 Life Sciences/Roche).ResultsRats treated with lansoprazole showed significantly reduced body weights compared to controls (lansoprazole-treated rats and controls, 322.3±15.3 g vs 403.2±5.2 g, respectively, p<0.001). However, stool frequencies and consistencies did not differ between the two groups. The composition of the gut microbiota in lansoprazole-treated rats was quite different from that of the controls. In the controls, the microbiota profiles obtained from the terminal ileum showed a predominance of Proteobacteria (93.9%) due to the abundance of Escherichia and Pasteurella genera. Conversely, lansoprazole-treated rats showed an elevated population of Firmicutes (66.9%), which was attributed to an increased ratio of Clostridium g4 to Lactobacillus genera.ConclusionsThis preliminary study suggests that long-term administration of PPI may cause weight loss and changes to the microbiota in the terminal ileum.

show abstract

“…Its presence might be essential for a mucosal adherent network of beneficial microorganisms that together prompt these effects of the host. As a matter of fact, weight loss studies usually report increased abundance of Verrucomicrobia (mainly Akkermansia muciniphila) as well as several other microbial species (Liou et al 2013, Remely et al 2015, Ward et al 2014. Taken together, these results further indicate the possible importance of mucosa-associated microbial networks and their metabolic cross-feeding for regulation of host health-related parameters and prevention of disease.…”

Section: Chaptermentioning

confidence: 72%

Cross-feeding interactions of gut symbionts driven by human milk oligosaccharidesand mucins

Chia¹

View full text Add to dashboard Cite

Chapter 4Microbial metabolic networks at the mucus layer lead to dietindependent butyrate and vitamin B12 production by intestinal symbionts 71 Chapter 5Deciphering trophic interaction between Akkermansia muciniphila and the butyrogenic gut commensal Anaerostipes caccae using a metatranscriptomic approach 97 Chapter 6General discussion 123 Chapter 7 Thesis summary & Nederlandse samenvatting 143 Appendices References 153Co-author affiliations 179Acknowledgements 183About the author 184List of publications 185 VLAG training activities 186Chapter 1 General introduction and thesis outlineChapter 1 2 General introductionHumans can be considered holobionts, consisting of cells from the host and an even larger number of microorganisms (Postler and Ghosh 2017). The majority of microbes are residing in the gut (Sender et al 2016). The human gut microbiota is a complex ecosystem consisting of bacteria, archaea, microeukaryotes and viruses (Clemente et al 2012). Over 2000 species-level phylotypes (prokaryotes including bacteria and archaea) have been detected for the gut microbiota, with each individual estimated to host at least 160 species (Qin et al 2010, Zoetendal et al 2008. The gut microbiota may impact the well-being of human and susceptibility for diseases by interacting with our metabolic, immune and neurological system (Honda and Littman 2016, Koh et al 2016, Rogers et al 2016. Furthermore, the gut microbiota contributes to a variety of metabolic functions and can be seen as an essential part of our digestive system (El Kaoutari et al 2013). Bacterial symbionts allow the human hosts to utilise inaccessible nutrients by converting complex substrates to short chain fatty acid (SCFA) and vitamins (Fisher et al 2017). Bacterial-derived SCFAs are estimated to contribute about 10% of our daily caloric requirement (Bergman 1990). While all SCFAs are vital for maintaining gut homeostasis, butyrate is of particular interest because it has been attributed to a range of health-promoting functions. Butyrate is the primary energy source for colonic epithelial cells and is associated with the enhancement of colonic barrier function, increase of satiety, pain relief, anti-inflammatory responses, and protection against colorectal cancer (Banasiewicz et al 2013, Bolognini et al 2016, Donohoe et al 2011, Furusawa et al 2013, Goncalves and Martel 2013.Considering the physiological benefits of butyrate to human health, this thesis investigates the microbial interaction of gut symbionts that support butyrate production driven primarily by the host produced glycans in human milk and mucus. Glycans are compounds consisting of an array of glycosidically linked monosaccharides (monosaccharides and disaccharides are collectively termed sugars) such as human milk oligosaccharides (HMOS) and mucins (Varki and Kornfeld 2017). HMOS present in mother milk are the major compositional and functional driver of the infant gut microbiota (Backhed et al 2015). Mucin glycans covering the intestinal lining create a stable niche for bacterial coloni...

show abstract

The Effect of PPI Use on Human Gut Microbiota and Weight Loss in Patients Undergoing Laparoscopic Roux-en-Y Gastric Bypass

Cited by 44 publications

References 20 publications

Antibiotic and acid-suppression medications during early childhood are associated with obesity

Antibiotic and acid-suppression medications during early childhood are associated with obesity

Impact of Long-Term Proton Pump Inhibitor Therapy on Gut Microbiota in F344 Rats: Pilot Study

Cross-feeding interactions of gut symbionts driven by human milk oligosaccharidesand mucins

Contact Info

Product

Resources

About